Detalhe da pesquisa
1.
AZGP1 deficiency promotes angiogenesis in prostate cancer.
J Transl Med
; 22(1): 383, 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38659028
2.
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
Br J Cancer
; 129(11): 1818-1828, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37798372
3.
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Proc Natl Acad Sci U S A
; 117(4): 2032-2042, 2020 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932422
4.
Protein signatures to distinguish aggressive from indolent prostate cancer.
Prostate
; 82(5): 605-616, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35098564
5.
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
Br J Cancer
; 124(5): 896-900, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33288843
6.
Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging.
Int J Cancer
; 147(1): 256-265, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31863456
7.
Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.
Proc Natl Acad Sci U S A
; 114(13): 3334-3339, 2017 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28292895
8.
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics.
Angew Chem Int Ed Engl
; 56(31): 8992-8997, 2017 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28649697
9.
Biologic differences between peripheral and transition zone prostate cancer.
Prostate
; 75(2): 183-90, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25327466
10.
Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.
Lab Invest
; 94(2): 208-21, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24296879
11.
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Int J Cancer
; 134(10): 2322-9, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24243565
12.
A tissue graft model of DNA damage response in the normal and malignant human prostate.
J Urol
; 191(3): 842-9, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24035881
13.
Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology.
Sci Rep
; 14(1): 5284, 2024 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438436
14.
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Cell Rep Med
; 5(2): 101381, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244540
15.
Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.
J Transl Med
; 11: 199, 2013 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23985008
16.
Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.
Drug Dev Res
; 74(2): 65-80, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25152555
17.
Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.
JCO Precis Oncol
; 7: e2200668, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285559
18.
Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
J Urol
; 188(6): 2158-64, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23088973
19.
Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma.
Metabolites
; 12(11)2022 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36422257
20.
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Cell Rep Med
; 3(2): 100502, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243415